First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism

Inclusion Criteria: General Inclusion Criteria: 1. Willing and able to provide informed consent; 2. 18 years of age and less than 75 years of age; 3. PE symptom duration ≤ 14 days; 4. Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT; 5. RV/LV end diastolic diameter ratio ≥ 0.9 by CTA as determined by the investigative site; 6. Willing and able to comply with all study procedures and follow-up. Exclusion Criteria: 1. Cerebrovascular Accident (CVA) or transient ischemic attack (TIA) within one (1) year; 2. Head trauma, or other active intracranial, or intraspinal disease within one (1) year; 3. Recent (within one month) or active bleeding from a major organ; 4. Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms); 5. Patients with bleeding diathesis; 6. Hematocrit \< 30%; 7. Platelets \< 100,000/μL; 8. INR \> 1.5; 9. aPTT \> 50 seconds in the absence of anticoagulants; 10. Major surgery within fourteen (14) days; 11. Serum creatinine \> 2 mg/dL; 12. Clinician deems high-risk for catastrophic bleeding; 13. History of heparin-induced thrombocytopenia (HIT); 14. Pregnancy; 15. Systolic blood pressure \< 90 mmHg for \> 15 minutes; 16. Any vasopressor support; 17. Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR); 18. Evidence of irreversible neurological compromise; 19. Life expectancy \< one (1) year; 20. Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study; 21. Use of non-vitamin K oral anti-coagulants (NOACs), such as Rivaroxaban, Apixaban, Dabigatran, Edoxaban within 48 hours prior to inclusion in the study; 22. Use of enoxaparin sodium injection (Lovenox®) within 12 hours of procedure start time; 23. Profound bradycardia requiring a temporary pacemaker and/or inotropic support; 24. Previous enrollment in this study; 25. Morbidly obese (BMI \>45 kg/m2) patient who by the judgement of the investigator is high risk for bleeding; 26. Absolute contraindication to anticoagulation; 27. Uncontrolled hypertension; 28. Currently participating in another study; 29. In the opinion of the investigator, the subject is not a suitable candidate for the study.